Utama › Kanser Payudara Triple-Negatif
Kajian klinikal Kanser Payudara Triple-Negatif sedang mengambil peserta di AS
147 kajian untuk Kanser Payudara Triple-Negatif sedang mengambil peserta di lokasi seluruh Amerika Syarikat.
Bandar dengan paling banyak kajian
- Houston, TX42 kajian
- New York City, NY31 kajian
- Nashville, TN28 kajian
- Los Angeles, CA27 kajian
- Boston, MA26 kajian
- San Antonio, TX23 kajian
- St. Louis, MO21 kajian
- Atlanta, GA20 kajian
- Arlington, VA20 kajian
- Dallas, TX18 kajian
- Chicago, IL16 kajian
- Columbus, OH16 kajian
- Tampa, FL15 kajian
- New Haven, CT15 kajian
- Grand Rapids, MI15 kajian
- Queens, NY15 kajian
- Seattle, WA14 kajian
- Austin, TX13 kajian
- Philadelphia, PA13 kajian
- West Valley City, UT13 kajian
- San Diego, CA13 kajian
- Durham, NC12 kajian
- Orlando, FL12 kajian
- Denver, CO12 kajian
- Baltimore, MD12 kajian
- Rochester, MN11 kajian
- Washington, DC11 kajian
- Pittsburgh, PA11 kajian
- Edison, NJ11 kajian
- Miami, FL11 kajian
- San Francisco, CA11 kajian
- Baldwin Park, CA10 kajian
- Cleveland, OH10 kajian
- Salt Lake City, UT9 kajian
- Oklahoma City, OK9 kajian
- Jacksonville, FL9 kajian
- Detroit, MI9 kajian
- Indianapolis, IN9 kajian
- Aurora, CO9 kajian
- Portland, OR9 kajian
Mengikut negeri
- Alabama11 kajian
- Arizona18 kajian
- Arkansas3 kajian
- California53 kajian
- Colorado21 kajian
- Connecticut19 kajian
- Delaware3 kajian
- Florida47 kajian
- Georgia26 kajian
- Illinois20 kajian
- Indiana13 kajian
- Iowa8 kajian
- Kansas5 kajian
- Kentucky6 kajian
- Louisiana6 kajian
- Maine3 kajian
- Maryland18 kajian
- Massachusetts26 kajian
- Michigan28 kajian
- Minnesota17 kajian
- Missouri24 kajian
- Nebraska6 kajian
- Nevada6 kajian
- New Jersey20 kajian
- New Mexico3 kajian
- New York46 kajian
- North Carolina21 kajian
- Ohio29 kajian
- Oklahoma10 kajian
- Oregon12 kajian
- Pennsylvania23 kajian
- Rhode Island4 kajian
- South Carolina9 kajian
- South Dakota7 kajian
- Tennessee31 kajian
- Texas59 kajian
- Utah23 kajian
- Virginia28 kajian
- Washington20 kajian
- Wilayah Columbia7 kajian
- Wisconsin7 kajian
Kajian yang dikemas kini baru-baru ini
Teks kajian rasmi (Bahasa Inggeris)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Mengambil pesertaFasa 1/2
Umur 12 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT04585750A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06465069A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06270706Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
Mengambil pesertaKajian pemerhatian
Umur 18 hingga 120 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT07619534A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Mengambil pesertaFasa 1
Umur 19 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06586957177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT07189871PRE-ISPY Phase I/II Oncology Platform Program
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT05868226Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT05422794First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Sep 2026 · NCT06799065Study of AVZO-021 in Patients With Advanced Solid Tumors
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT05867251Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
Mengambil peserta
Umur 30 ke atas · Wanita · Dikemas kini 25 Sep 2026 · NCT02945579A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06966700Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT04981119Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06393374A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06841354Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC
Mengambil peserta
Umur 18 ke atas · Wanita · Dikemas kini 25 Sep 2026 · NCT07066189Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT05528133A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT07229313Intratumoral N17350 in Advanced Solid Tumors
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT07339176A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT06618287Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 21 Sep 2026 · NCT05983432Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Sep 2026 · NCT07340541A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Sep 2026 · NCT07705334A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Sep 2026 · NCT07020117Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Sep 2026 · NCT06353997Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.